Table 3.

Parameter estimates of the population pharmacokinetic model

Parameter	Units	Estimate	RSEa, %	Description
${\text{CL}}^{\text{KOV}}$	dL/h	1.51	7.33	Clearance of BAY 81-8973
$V{1}^{\text{KOV},\text{ADV}}$	dL	23.6	2.76	Central volume of distribution of BAY 81-8973 and rAHF-PFM
$Q^{\text{KOV},\text{ADV}}$	dL/h	1.59	5.5	Intercompartmental clearance of BAY 81-8973 and rAHF-PFM
$V{2}^{\text{KOV}}$	dL	5.35	12.8	Peripheral volume of distribution of BAY 81-8973
$\mathrm{\Delta }{\text{CL}}^{\text{ADV}}$	%	47.8	8.05	Change in clearance for rAHF-PFM compared with BAY 81-8973
$\mathrm{\Delta }V{2}^{\text{ADV}}$	%	86.6	23.4	Change in peripheral volume of distribution for rAHF-PFM compared with BAY 81-8973
${\text{IIV}}_{\text{Cl}}$	CV %b	27.2	13.9	Intraindividual variability in clearance
${\text{IIV}}_{V_1}$	CV %b	7.93	36.9	Intraindividual variability in central volume of distribution
${\text{IIV}}_{\mathrm{\Delta }\text{Cl}}$	CV %b	35	27.1	Intraindividual variability in change in clearance
${\text{IOV}}_{F_1}$	CV %b	10.3	31.7	Intraoccasional variability in bioavailability
${\mathit{\epsilon }}_{\text{prop}}$	CV %c	5.73	6.84	Proportional residual error

CV coefficient of variation, rAHF-PFM antihemophilic factor (recombinant) plasma/albumin-free method, RSE relative standard error, SQRT square root

^aAssessed via bootstrap (n = 500, with 485 successful runs)

^bCalculated by SQRT(EXP(variance) − 1) × 100

^cCalculated by SQRT(variance) × 100